OMER Rises +11.8% After EMA Panel Backs Negative View
Omeros (OMER) shares rose +11.8% on Jul 6, 2026 after the company disclosed an update from Europe’s drug-review process for narsoplimab.
What Omeros announced
Omeros said it provided an update on the Committee for Medicinal Products for Human Use (CHMP) review at the European Medicines Agency (EMA) of its marketing authorization application (MAA) for narsoplimab. The filing is for narsoplimab to treat hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA).
According to the company, after an oral explanation meeting with the CHMP held that week — where Omeros presented its position alongside four international experts in hematopoietic cell transplantation — it was informed that the CHMP adopted a negative opinion on the MAA for narsoplimab in TA-TMA.
Separately, the summary also referenced a law firm investigation into whether the company issued false and/or misleading statements or failed to disclose information pertinent to investors.
What it means for Omeros
A negative CHMP opinion is a setback for Omeros’ effort to win European marketing authorization for narsoplimab in TA-TMA, based on the company’s own description of the review outcome. The update also shows the company engaged directly with regulators through an oral explanation meeting and brought in outside experts to support its case.
The mention of a securities-law investigation adds another layer of potential overhang, since such probes can raise questions about prior disclosures and increase legal costs or management distraction. At the same time, the market’s move suggests traders were actively repricing the situation after the update became public.
How the stock reacted
OMER climbed quickly after the news and held gains into the close.
| Window | Move |
|---|---|
| 5 min | +6.5% |
| 10 min | +7.2% |
| 30 min | +9.5% |
| 1 hour | +9.1% |
| end of day | +11.8% |
On a market-adjusted basis, the stock’s same-day move was +11.4% versus the S&P 500 ETF (SPY).